- POINT Biopharma Global Inc (NASDAQ:PNT) priced its public offering of 13.9 million shares at $9.00 per share, with gross proceeds of $125 million.
- The offer price represents a discount of almost 12% from the last close price of $10.18 on Tuesday.
- Underwriters have an option to purchase up to an additional 2.01 million shares.
- POINT will use the proceeds to fund clinical and preclinical research and development programs.
- Related: POINT Biopharma Shares Jump After Updated Efficacy, Safety Data From Prostate Cancer Candidate.
- Akero Therapeutics Inc (NASDAQ:AKRO) commenced an underwritten public offering of $175.0 million.
- Underwriters have an option to purchase up to an additional $26.25 million of shares.
- Related: Akero Therapeutics Shares More Than Double After Lead NASH Candidate Aces Mid-Stage Study
- Price Action: AKRO shares are down 6.51% at $27.16, and PNT shares are down 11.40% at $9.02 on the last check Wednesday.
Deutsche Bank Maintains Buy on AdaptHealth, Raises Price Target to $28
Deutsche Bank analyst Pito Chickering maintains AdaptHealth (NASDAQ:AHCO) with a Buy and raises the price target from $26 to $28.
